Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie’s Disease with Calcified Plaques
- 19 October 2022
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 9 (1) , 55-59
Abstract
No abstract availableKeywords
Funding Information
- Enzon Pharmaceuticals
This publication has 9 references indexed in Scilit:
- Assessment of Conservative Combination Therapies for Active and Stable Peyronie’s Disease: A Systematic Review and Meta-analysisEuropean Urology Focus, 2022
- Penile surgery for patients with Peyronie’s disease initially treated with collagenase clostridium histolyticum or surgery: a claims database analysisInternational Journal Of Impotence Research, 2022
- Implications of Calcification in Peyronie's Disease, A Review of the LiteratureUrology, 2021
- Plaque Calcification: An Important Predictor of Collagenase Clostridium Histolyticum Treatment Outcomes for Men With Peyronie's DiseaseUrology, 2018
- Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie’s DiseaseJournal of Urology, 2016
- Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double‐blind, randomized, placebo‐controlled, phase III studiesBJU International, 2015
- Peyronie's Disease Plaque Calcification—Prevalence, Time to Identification, and Development of a New Grading ClassificationThe Journal of Sexual Medicine, 2013
- Clinical Efficacy, Safety and Tolerability of Collagenase Clostridium Histolyticum for the Treatment of Peyronie Disease in 2 Large Double-Blind, Randomized, Placebo Controlled Phase 3 StudiesJournal of Urology, 2013
- Peyronie’s Disease: Review of Nonsurgical Treatment OptionsUrologic Clinics of North America, 2011